Randomized Study Comparing Cell Therapeutics' OPAXIO and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment

Cell Therapeutics, Inc CTIC announced that enrollment has opened for a randomized phase II clinical study comparing the combination of OPAXIO (paclitaxel poliglumex, PPX) and radiation to the combination of temozolomide and RT for patients with newly diagnosed glioblastoma, a high-grade malignant brain tumor. The objectives of the study are to determine if OPAXIO and RT improve progression free survivaland overall survival compared to TMZ and RT as well as to evaluate neuro-cognitive function and toxicities of these therapies. If positive, results from the study could be used to plan a phase III study of OPAXIO added to standard radiation therapy for approval in this disease.